Focused On-demand Library for Eukaryotic translation initiation factor 4 gamma 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q04637

UPID:

IF4G1_HUMAN

Alternative names:

p220

Alternative UPACC:

Q04637; D3DNT2; D3DNT4; D3DNT5; E9PFM1; G5E9S1; O43177; O95066; Q5HYG0; Q6ZN21; Q8N102

Background:

Eukaryotic translation initiation factor 4 gamma 1 (EIF4G1), also known as p220, plays a pivotal role in the initiation of protein synthesis. It is a component of the eIF4F complex, crucial for mRNA cap recognition, ATP-dependent mRNA unwinding, and ribosome recruitment. EIF4G1 operates in distinct complexes, influencing mRNA scanning and start codon selection, and is essential for ATF4 mRNA translation under endoplasmic reticulum stress.

Therapeutic significance:

EIF4G1's mutation is linked to Parkinson disease 18, a late-onset, autosomal dominant form characterized by neurodegeneration and Lewy body accumulation. Understanding the role of EIF4G1 could open doors to potential therapeutic strategies for Parkinson's and related neurodegenerative disorders.